The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase III randomized trial of pembrolizumab in combination with sacituzumab govitecan vs standard of care in anti–PD-(L)1–resistant advanced urothelial cancer: ECOG-ACRIN EA8231.
 
Monika Joshi
Honoraria - Curio Science; IDEOlogy Health; OncLive
Consulting or Advisory Role - Eisai; Gilead Sciences; Seagen
Research Funding - AstraZeneca (Inst); BMS (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Caris Life Sciences; DAVA Oncology
 
Se Kim
No Relationships to Disclose
 
Petros Grivas
Consulting or Advisory Role - Abbvie; Astellas Pharma; AstraZeneca; Bicycle Therapeutics; Bristol-Myers Squibb; Daiichi Sankyo; EMD Serono; Foundation Medicine; Gilead Sciences; Janssen; Lilly; Merck; Natera; Pfizer; Replimune; Roche; Strata Oncology; Tyra Biosciences; Urogen pharma
Research Funding - Acrivon Therapeutics (Inst); ALX Oncology (Inst); EMD Serono (Inst); Genentech (Inst); Gilead Sciences (Inst); Merck (Inst)
Travel, Accommodations, Expenses - Gilead Sciences
 
Elizabeth Wulff
Stock and Other Ownership Interests - Immunomedics (I); Nektar (I)
Honoraria - OncologyLive
Consulting or Advisory Role - Aptitude Health; Astellas Scientific and Medical Affairs Inc; AstraZeneca; AVEO; Bristol-Myers Squibb; Exelixis; Janssen Oncology; Targeted Oncology
Research Funding - Acerta Pharma/AstraZeneca (Inst); Pfizer
Patents, Royalties, Other Intellectual Property - Methods of use patent application has been submitted for the pharmaceutical product Osanetant, owned by Acer Therapeutics.
Travel, Accommodations, Expenses - Exelixis
 
Alicia Morgans
Employment - Dana-Farber Cancer Institute
Stock and Other Ownership Interests - Vertex (I)
Honoraria - Advanced Accelerator Applications; Astellas Scientific and Medical Affairs Inc; AstraZeneca; Bayer; Curium Pharma; Exelixis; Janssen; Lantheus Medical Imaging; Macrogenics; Merck; Novartis; Pfizer; Sumitomo Pharma Oncology; Telix Pharmaceuticals; Tolmar
Consulting or Advisory Role - Advanced Accelerator Applications; Astellas Pharma; AstraZeneca; Bayer; Johnson & Johnson/Janssen; Lantheus Medical Imaging; Merck; Novartis; Sumitomo Pharma Oncology
Research Funding - Astellas Scientific and Medical Affairs Inc; AstraZeneca; Bayer; Bristol Myers Squibb Foundation; Exact Sciences; Myovant Sciences; Pfizer; Sumitomo Pharma Oncology
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Bayer; Novartis; Novartis; Pfizer
 
Kriti Mittal
Honoraria - Aptitude Health; Cardinal Health; IntrinsiQ; Medpage; Research to Practice; Research to Practice; Targeted Oncology; Targeted Oncology
Consulting or Advisory Role - AstraZeneca; Aveo; AVEO; Curio Science; Dendreon; Janssen; Myovant Sciences
Research Funding - Pfizer
 
Joshua Warrick
Research Funding - AstraZeneca (Inst)
 
Melissa Reimers
Consulting or Advisory Role - Astellas Pharma; Cicadea Biotech; Eisai; EMD Serono; Lilly; Loxo; Pathos AI, Inc
Research Funding - Amgen (Inst); Arcus Biosciences (Inst); AstraZeneca (Inst); BMS GmbH & Co. KG (Inst); crispr therapeutics (Inst); Eisai (Inst); Exelixis (Inst); FORMA Therapeutics (Inst); Genentech (Inst); Janssen (Inst); Lilly (Inst); Loxo (Inst); Merck (Inst); ProfoundBio (Inst)
 
Noah Hahn
Honoraria - Cancer Panels
Consulting or Advisory Role - Asieris Pharmaceuticals; AstraZeneca; Cadence Cancer Research; Merck; Pfizer; Pfizer; Protara Therapeutics; Society of Urologic Oncology; Tyra Biosciences
Research Funding - AstraZeneca/MedImmune (Inst); Daiichi Sankyo/Astra Zeneca (Inst); EMD Serono/Merck (Inst); ImmunityBio (Inst); Incyte (Inst); Predicine (Inst)
Patents, Royalties, Other Intellectual Property - Publication number: 20240076747 Abstract: Provided herein are methods of determining treatment outcome in a subject having a disease, the method including evaluating RNA expression level of a B cell related gene to determine a B cell gene signature; evalu
 
Naomi Haas
Leadership - ECOG-ACRIN
Consulting or Advisory Role - Eisai; Merck Sharp & Dohme
 
Lynne Wagner
Consulting or Advisory Role - Celgene; TheraBionic, Inc.
 
Michael Carducci
Honoraria - Remedica
Consulting or Advisory Role - Acrivon Therapeutics; Amgen; AstraZeneca; Pfizer